124 related articles for article (PubMed ID: 9157075)
1. 13-Cis-retinoic acid and interferon alpha-2a in patients with advanced esophageal cancer: a phase II trial.
Slabber CF; Falkson G; Burger W; Schoeman L
Invest New Drugs; 1996; 14(4):391-4. PubMed ID: 9157075
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.
Enzinger PC; Ilson DH; Saltz LB; Martin LK; Kelsen DP
Cancer; 1999 Mar; 85(6):1213-7. PubMed ID: 10189124
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
Skeel RT; Huang J; Manola J; Wilding G; Dreicer R; Walker P; Muggia F; Crawford ED; Dutcher JP; Loehrer PJ
Cancer Invest; 2003; 21(1):41-6. PubMed ID: 12643008
[TBL] [Abstract][Full Text] [Related]
4. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin.
Lippman SM; Parkinson DR; Itri LM; Weber RS; Schantz SP; Ota DM; Schusterman MA; Krakoff IH; Gutterman JU; Hong WK
J Natl Cancer Inst; 1992 Feb; 84(4):235-41. PubMed ID: 1734084
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
[TBL] [Abstract][Full Text] [Related]
6. 13-cis-retinoic acid and alpha-interferon in advanced squamous cell cancer of the oesophagus.
Kok TC; van der Gaast A; Splinter TA
Eur J Cancer; 1997 Jan; 33(1):165-6. PubMed ID: 9071918
[No Abstract] [Full Text] [Related]
7. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Wadler S; Fell S; Haynes H; Katz HJ; Rozenblit A; Kaleya R; Wiernik PH
Cancer; 1993 Mar; 71(5):1726-30. PubMed ID: 8448736
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Fleming GF; O'Brien SM; Hoffman PC; Vokes EE; Vogelzang NJ; Schilsky RL; Waggoner SE; Ratain MJ
Cancer Chemother Pharmacol; 1997; 39(3):227-32. PubMed ID: 8996525
[TBL] [Abstract][Full Text] [Related]
10. [13-cis retinoic acid and interferon-alfa-2a as palliative therapy in pretreated, recurrent squamous epithelial carcinoma of the cervix uteri and vulva].
Römisch M; Meier W; Kimmig R; Hepp H
Geburtshilfe Frauenheilkd; 1996 Oct; 56(10):520-4. PubMed ID: 9036064
[TBL] [Abstract][Full Text] [Related]
11. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix.
Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Holdener E; Krakoff IH
J Natl Cancer Inst; 1992 Feb; 84(4):241-5. PubMed ID: 1734085
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma.
Gravis G; Pech-Gourgh F; Viens P; Alzieu C; Camerlo J; Oziel-Taieb S; Jausseran M; Maraninchi D
Anticancer Drugs; 1999 Apr; 10(4):369-74. PubMed ID: 10378671
[TBL] [Abstract][Full Text] [Related]
13. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.
Pazdur R; Bready B; Ajani JA; Abbruzzese JL; Markowitz A; Sugarman S; Jones D; Levin B
Am J Clin Oncol; 1995 Oct; 18(5):436-8. PubMed ID: 7572763
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma.
Vaishampayan U; Flaherty L; Du W; Hussain M
Cancer; 2001 Aug; 92(3):519-23. PubMed ID: 11505395
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma.
Toma S; Palumbo R; Vincenti M; Aitini E; Paganini G; Pronzato P; Grimaldi A; Rosso R
Ann Oncol; 1994 May; 5(5):463-5. PubMed ID: 8075053
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
Rinaldi DA; Lippman SM; Burris HA; Chou C; Von Hoff DD; Hong WK
Anticancer Drugs; 1993 Feb; 4(1):33-6. PubMed ID: 8457712
[TBL] [Abstract][Full Text] [Related]
19. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
Bazarbashi S; Rahal M; Raja MA; El Weshi A; Pai C; Ezzat A; Ajarim D; Memon M; Al Fadda M
Chemotherapy; 2002 Sep; 48(4):211-6. PubMed ID: 12218269
[TBL] [Abstract][Full Text] [Related]
20. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix.
Lippman SM; Kavanagh JJ; Paredes-Espinoza M; Delgadillo-Madrueño F; Paredes-Casillas P; Hong WK; Massimini G; Holdener EE; Krakoff IH
J Natl Cancer Inst; 1993 Mar; 85(6):499-500. PubMed ID: 8445678
[No Abstract] [Full Text] [Related]
[Next] [New Search]
